ArticleJournal of fungi (Basel, Switzerland)2022
Nationwide Surveillance of Antifungal Resistance of
Article in Journal of fungi (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 18 citations in OpenAlex.
- High Burden of Invasive Fungal Infection in Korean Pediatric Liver Transplant Recipients: A Single-Center Retrospective Cohort Study (2012-2023).Yonsei medical journal · 2026Article
- Clinical Characteristics and Mortality Risk Factors ofAnnals of laboratory medicine · 2026Article
- Epidemiology and Characteristics of Invasive Yeast Infections in Patients with Hematologic Diseases: 12-Year Single-Center Retrospective Cohort Study.Journal of fungi (Basel, Switzerland) · 2025Article
- Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives.Infectious disease reports · 2025Review
- Epidemiology and Clinical Features ofJournal of fungi (Basel, Switzerland) · 2025Article
- Comparative Performance Evaluation of Continuous Monitoring Blood Culture Systems Using Simulated Septic Specimen.Diagnostics (Basel, Switzerland) · 2025Article
- Detection of clinically relevant Candida species from positive blood cultures using a novel sample-to-answer molecular assay.Scientific reports · 2025Article
- Phenotypic and genotypic characterization of Candida parapsilosis complex isolates from a Lebanese hospital.Scientific reports · 2025Article
- Changes in Candidemia during the COVID-19 Pandemic: Species Distribution, Antifungal Susceptibility, Initial Antifungal Usage, and Mortality Trends in Two Korean Tertiary Care Hospitals.Chonnam medical journal · 2025Article
- Nosocomial transmission of fluconazole-resistantMicrobiology spectrum · 2024Article
- Clinical Characteristics of Candidemia Due toJournal of fungi (Basel, Switzerland) · 2024Article
- Changing Epidemiology of Clinical Isolates ofJournal of fungi (Basel, Switzerland) · 2024Article
- Trends in antifungal resistance inAntimicrobial agents and chemotherapy · 2023Article
- Virulence Traits and Azole Resistance in KoreanJournal of fungi (Basel, Switzerland) · 2023Article
- Evaluation of Fluconazole versus Echinocandins for Treatment of Candidemia Caused by Susceptible CommonJournal of fungi (Basel, Switzerland) · 2023Article
- InvasiveMicroorganisms · 2023Article
- Phaeohyphomycosis due toMycobiology · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 1 country.
Funding
Abstract
We incorporated nationwide Candida antifungal surveillance into the Korea Global Antimicrobial Resistance Surveillance System (Kor-GLASS) for bacterial pathogens. We prospectively collected and analyzed complete non-duplicate blood isolates and information from nine sentinel hospitals during 2020−2021, based on GLASS early implementation protocol for the inclusion of Candida species. Candida species ranked fourth among 10,758 target blood pathogens and second among 4050 hospital-origin blood pathogens. Among 766 Candida blood isolates, 87.6% were of hospital origin, and 41.3% occurred in intensive care unit patients. Adults > 60 years of age accounted for 75.7% of cases. Based on species-specific clinical breakpoints, non-susceptibility to fluconazole, voriconazole, caspofungin, micafungin, and anidulafungin was found in 21.1% (154/729), 4.0% (24/596), 0.1% (1/741), 0.0% (0/741), and 0.1% (1/741) of the isolates, respectively. Fluconazole resistance was determined in 0% (0/348), 2.2% (3/135, 1 Erg11 mutant), 5.3% (7/133, 6 Pdr1 mutants), and 5.6% (6/108, 4 Erg11 and 1 Cdr1 mutants) of C. albicans, C. tropicalis, C. glabrata, and C. parapsilosis isolates, respectively. An echinocandin-resistant C. glabrata isolate harbored an F659Y mutation in Fks2p. The inclusion of Candida species in the Kor-GLASS system generated well-curated surveillance data and may encourage global Candida surveillance efforts using a harmonized GLASS system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.